HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe
OBJECTIVES: To analyze the patterns and risk factors of HIV drug resistance mutations among patients failing second-line treatment and to describe early treatment responses to recommended third-line antiretroviral therapy (ART) in a national referral HIV clinic in Zimbabwe. METHODS: Patients on boos...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801603/ https://www.ncbi.nlm.nih.gov/pubmed/29435471 http://dx.doi.org/10.1093/ofid/ofy005 |
_version_ | 1783298377743597568 |
---|---|
author | Chimbetete, Cleophas Katzenstein, David Shamu, Tinei Spoerri, Adrian Estill, Janne Egger, Matthias Keiser, Olivia |
author_facet | Chimbetete, Cleophas Katzenstein, David Shamu, Tinei Spoerri, Adrian Estill, Janne Egger, Matthias Keiser, Olivia |
author_sort | Chimbetete, Cleophas |
collection | PubMed |
description | OBJECTIVES: To analyze the patterns and risk factors of HIV drug resistance mutations among patients failing second-line treatment and to describe early treatment responses to recommended third-line antiretroviral therapy (ART) in a national referral HIV clinic in Zimbabwe. METHODS: Patients on boosted protease inhibitor (PI) regimens for more than 6 months with treatment failure confirmed by 2 viral load (VL) tests >1000 copies/mL were genotyped, and susceptibility to available antiretroviral drugs was estimated by the Stanford HIVdb program. Risk factors for major PI resistance were assessed by logistic regression. Third-line treatment was provided as Darunavir/r, Raltegravir, or Dolutegravir and Zidovudine, Abacavir Lamivudine, or Tenofovir. RESULTS: Genotypes were performed on 86 patients who had good adherence to treatment. The median duration of first- and second-line ART was 3.8 years (interquartile range [IQR], 2.3–5.1) and 2.6 years (IQR, 1.6–4.9), respectively. The median HIV viral load and CD4 cell count were 65 210 copies/mL (IQR, 8728–208 920 copies/mL) and 201 cells/mm(3) (IQR, 49–333 cells/mm(3)). Major PI resistance-associated mutations (RAMs) were demonstrated in 44 (51%) non-nucleoside reverse transcriptase inhibitor RAMs in 72 patients (83%) and nucleoside reverse transcriptase inhibitors RAMs in 62 patients (72%). PI resistance was associated with age >24 years (P = .003) and CD4 cell count <200 cells/mm(3) (P = .007). In multivariable analysis, only age >24 years was significantly associated (adjusted odds ratio, 4.75; 95% confidence interval, 1.69–13.38; P = .003) with major PI mutations. Third-line DRV/r- and InSTI-based therapy achieved virologic suppression in 29/36 patients (81%) after 6 months. CONCLUSIONS: The prevelance of PI mutations was high. Adolescents and young adults had a lower risk of acquiring major PI resistance mutations, possibly due to poor adherence to ART. Third-line treatment with a regimen of Darunavir/r, Raltegravir/Dolutegravir, and optimized nucleoside reverse transcriptase inhibitors was effective. |
format | Online Article Text |
id | pubmed-5801603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58016032018-02-12 HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe Chimbetete, Cleophas Katzenstein, David Shamu, Tinei Spoerri, Adrian Estill, Janne Egger, Matthias Keiser, Olivia Open Forum Infect Dis Major Article OBJECTIVES: To analyze the patterns and risk factors of HIV drug resistance mutations among patients failing second-line treatment and to describe early treatment responses to recommended third-line antiretroviral therapy (ART) in a national referral HIV clinic in Zimbabwe. METHODS: Patients on boosted protease inhibitor (PI) regimens for more than 6 months with treatment failure confirmed by 2 viral load (VL) tests >1000 copies/mL were genotyped, and susceptibility to available antiretroviral drugs was estimated by the Stanford HIVdb program. Risk factors for major PI resistance were assessed by logistic regression. Third-line treatment was provided as Darunavir/r, Raltegravir, or Dolutegravir and Zidovudine, Abacavir Lamivudine, or Tenofovir. RESULTS: Genotypes were performed on 86 patients who had good adherence to treatment. The median duration of first- and second-line ART was 3.8 years (interquartile range [IQR], 2.3–5.1) and 2.6 years (IQR, 1.6–4.9), respectively. The median HIV viral load and CD4 cell count were 65 210 copies/mL (IQR, 8728–208 920 copies/mL) and 201 cells/mm(3) (IQR, 49–333 cells/mm(3)). Major PI resistance-associated mutations (RAMs) were demonstrated in 44 (51%) non-nucleoside reverse transcriptase inhibitor RAMs in 72 patients (83%) and nucleoside reverse transcriptase inhibitors RAMs in 62 patients (72%). PI resistance was associated with age >24 years (P = .003) and CD4 cell count <200 cells/mm(3) (P = .007). In multivariable analysis, only age >24 years was significantly associated (adjusted odds ratio, 4.75; 95% confidence interval, 1.69–13.38; P = .003) with major PI mutations. Third-line DRV/r- and InSTI-based therapy achieved virologic suppression in 29/36 patients (81%) after 6 months. CONCLUSIONS: The prevelance of PI mutations was high. Adolescents and young adults had a lower risk of acquiring major PI resistance mutations, possibly due to poor adherence to ART. Third-line treatment with a regimen of Darunavir/r, Raltegravir/Dolutegravir, and optimized nucleoside reverse transcriptase inhibitors was effective. Oxford University Press 2018-02-02 /pmc/articles/PMC5801603/ /pubmed/29435471 http://dx.doi.org/10.1093/ofid/ofy005 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
spellingShingle | Major Article Chimbetete, Cleophas Katzenstein, David Shamu, Tinei Spoerri, Adrian Estill, Janne Egger, Matthias Keiser, Olivia HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title_full | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title_fullStr | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title_full_unstemmed | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title_short | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe |
title_sort | hiv-1 drug resistance and third-line therapy outcomes in patients failing second-line therapy in zimbabwe |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801603/ https://www.ncbi.nlm.nih.gov/pubmed/29435471 http://dx.doi.org/10.1093/ofid/ofy005 |
work_keys_str_mv | AT chimbetetecleophas hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT katzensteindavid hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT shamutinei hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT spoerriadrian hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT estilljanne hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT eggermatthias hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe AT keiserolivia hiv1drugresistanceandthirdlinetherapyoutcomesinpatientsfailingsecondlinetherapyinzimbabwe |